Becker Tyson E, Ellsworth Rachel E, Deyarmin Brenda, Patney Heather L, Jordan Rick M, Hooke Jeffrey A, Shriver Craig D, Ellsworth Darrell L
Clinical Breast Care Project, Windber Research Institute, 620 Seventh Street, Windber, PA 15963, USA.
Ann Surg Oncol. 2008 Apr;15(4):1056-63. doi: 10.1245/s10434-008-9815-3. Epub 2008 Feb 2.
Metastatic breast cancer is an aggressive disease associated with recurrence and decreased survival. To improve outcomes and develop more effective treatment strategies for patients with breast cancer, it is important to understand the molecular mechanisms underlying metastasis.
We used allelic imbalance (AI) to determine the molecular heritage of primary breast tumors and corresponding metastases to the axillary lymph nodes. Paraffin-embedded samples from primary breast tumors and matched metastases (n = 146) were collected from 26 patients with node-positive breast cancer involving multiple axillary nodes. Hierarchical clustering was used to assess overall differences in the patterns of AI, and phylogenetic analysis inferred the molecular heritage of axillary lymph node metastases.
Overall frequencies of AI were significantly higher (P < 0.01) in primary breast tumors (23%) than in lymph node metastases (15%), and there was a high degree of discordance in patterns of AI between primary breast carcinomas and the metastases. Metastatic tumors in the axillary nodes showed different patterns of chromosomal changes, suggesting that multiple molecular mechanisms may govern the process of metastasis in individual patients. Some metastases progressed with few genomic alterations, while others harbored many chromosomal alterations present in the primary tumor.
The extent of genomic heterogeneity in axillary lymph node metastases differs markedly among individual patients. Genomic diversity may be associated with response to adjuvant therapy, recurrence, and survival, and thus may be important in improving clinical management of breast cancer patients.
转移性乳腺癌是一种侵袭性疾病,与复发和生存率降低相关。为改善乳腺癌患者的治疗效果并制定更有效的治疗策略,了解转移背后的分子机制很重要。
我们使用等位基因失衡(AI)来确定原发性乳腺肿瘤及相应腋窝淋巴结转移灶的分子遗传特征。从26例累及多个腋窝淋巴结的淋巴结阳性乳腺癌患者中收集原发性乳腺肿瘤及匹配转移灶的石蜡包埋样本(n = 146)。采用层次聚类分析评估AI模式的总体差异,并通过系统发育分析推断腋窝淋巴结转移灶的分子遗传特征。
原发性乳腺肿瘤中AI的总体频率(23%)显著高于淋巴结转移灶(15%)(P < 0.01),原发性乳腺癌与转移灶之间的AI模式存在高度不一致。腋窝淋巴结中的转移瘤表现出不同的染色体变化模式,这表明多种分子机制可能在个体患者的转移过程中起作用。一些转移灶进展时基因组改变很少,而另一些则含有原发性肿瘤中存在的许多染色体改变。
腋窝淋巴结转移灶中基因组异质性的程度在个体患者之间存在显著差异。基因组多样性可能与辅助治疗反应、复发和生存相关,因此在改善乳腺癌患者的临床管理中可能很重要。